Browse studies

Find your next paid study

121 recruiting studies matching your filters

(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000

This study will measure how well PathFinder 1.0 detects retinal abnormalities on macular cube OCT B-scans by assessing its sensitivity and specificity.

Epiretinal MembraneDry Age Related Macular DegenerationMacular Abnormalities+7 more

Estimated

~$10 – $7,500

Carl Zeiss Meditec-Dublin CoCeNCT07680244

Observational

Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration (i-SIGHT2): a Multicentre, Randomised, Sham-controlled, Double-masked, Clinical Device Trial.

The goal of this clinical trial is to characterize the safety and effectiveness of the i-Lumen AMD transpalpebral microcurrent device and therapy in patients w…

Estimated

~$10 – $8,750

i-Lumen Scientific AUS PTY LTDNCT06662162

Phase 2

Efficacy of Dapagliflozin in the Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration

AMD is a leading cause of blindness in individuals over 50 years old, with dry AMD being the most common form. Geographic atrophy (GA) is an advanced stage of …

Retinal DegenerationRetinal DiseasesEye Diseases+2 more

Estimated

~$10 – $6,250

Washington University School of MedicineNCT07174687

Observational

Open Label, Multi-Center Study, Evaluating the Effect of Adipose Tissue Processed With the SyntrFuge™ System for Facial Fat Grafting

This is an open label multi-center study with the aim of evaluating the efficacy of adipose tissue processed with the SyntrFuge™ system in facial aesthetics an…

Facial Atrophy and Loss of Contour

Estimated

~$10 – $8,750

Syntr Health Technologies, Inc.NCT05522426

Observational

Safety and Performance of the ThecaFlex DRx™ System Port and Catheter for Chronic Intrathecal Access, Cerebrospinal Fluid (CSF) Aspiration, and DElivery of Nusinersen in Spinal Muscular Atrophy (SMA) Patients Resistant to Lumbar PunctuRE Trial (PIERRE)

The primary objective of the clinical investigation is to demonstrate successful clinical use of the ThecaFlex DRx™ System in delivering nusinersen in subjects…

Spinal Muscular AtrophySpine DeformityScoliosis

Estimated

~$10 – $8,750

Alcyone Therapeutics, IncNCT05866419

Phase 3

An Open-Label Study to Assess the Efficacy and Safety of Multiple Doses of Salanersen (BIIB115) Delivered Intrathecally to Treatment-Naïve, Presymptomatic Infants With Genetically Diagnosed Spinal Muscular Atrophy

In this study, researchers will learn more about the effects and safety of BIIB115, also known as salanersen. Specifically, researchers will learn more about …

Muscular Atrophy, Spinal

A Phase I Single-Center Open-label Study of C.001 in Patients With Significant Retinal Pigment Epithelium Mediated Maculopathy (RMM)

This is a first-in-human Phase 1 study evaluating the safety and tolerability of C.001 in patients with retinal diseases involving degeneration of the retinal …

Geographic AtrophyStargardt DiseaseRPE-mediated Maculopathy+1 more

Estimated

~$10 – $8,750

Cellio Therapeutics IncNCT07594236

An Observational Study to Assess Clinical, Molecular and Imaging Biomarkers in Spinal and Bulbar Muscular Atrophy (SBMA)

Background: SBMA is an inherited chronic disease. It affects males in mid to late adulthood. It causes slowly progressive weakness of muscles and hand tremors…

Spinal and Bulbar Muscular AtrophyKennedys DiseaseMotor Neuron Disease

Estimated

~$10 – $675

National Institute of Neurological Disorders and Stroke (NINDS)NCT04944940

Phase 3

A Phase 3, Randomized, Double-Blinded Study to Evaluate the Safety and Efficacy of Salanersen (BIIB115) After Onasemnogene Abeparvovec Treatment in Infants With Genetically Diagnosed Spinal Muscular Atrophy

In this study, researchers will learn more about the safety and effects of BIIB115, also known as salanersen. Specifically, researchers will learn more about h…

Muscular Atrophy, Spinal

A Phase 1/2, First-in-Human, Multi-Arm, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of an Adeno-associated Virus Vector VV-14295 Administered Suprachoroidally With the Everads Injector In AdultS With GeographIc Atrophy Secondary to Age-related Macular DegeneratiON (the VISION Study)

The goal of this study is to evaluate how safe and tolerable KRIYA-825 (VV-14295) is and to determine how effective it is in reducing the growth of geographic …

Geographic Atrophy Secondary to Age-related Macular Degeneration

Estimated

~$10 – $8,750

Kriya Therapeutics, Inc.NCT06765980

Phase 1

A Phase 1 Dose-Escalation and Repeated-Dose Study of the Safety and Tolerability of Intravitreal Pozelimab in Participants With Geographic Atrophy

This study is researching an experimental drug called pozelimab (called "study drug"). The study is focused on people with a condition where certain parts of t…

Geographic Atrophy (GA)

Estimated

~$10 – $8,750

Regeneron PharmaceuticalsNCT07230834

Remote Monitoring in Progressive Supranuclear Palsy, an Alzheimer's Disease Related Dementia

This is a single-arm, longitudinal, observational study on the use of wearable sensors and digital health technology to measure fall frequency and motor, speec…

Progressive Supranuclear PalsyParkinson DiseaseMSA - Multiple System Atrophy

Estimated

~$10 – $750

Massachusetts General HospitalNCT04753320